CL2014000818A1 - Compuestos derivados de (fenil/heteroaril)-etinil-(piridin/pirimidin/piridazin)-acetamida, moduladores del receptor metabotropico de glutamato; procedimiento de preparacion; composicion farmaceutica; y su uso en esquizofrenia, enfermedades cognitivas, sindrome x-fragil o autismo - Google Patents
Compuestos derivados de (fenil/heteroaril)-etinil-(piridin/pirimidin/piridazin)-acetamida, moduladores del receptor metabotropico de glutamato; procedimiento de preparacion; composicion farmaceutica; y su uso en esquizofrenia, enfermedades cognitivas, sindrome x-fragil o autismoInfo
- Publication number
- CL2014000818A1 CL2014000818A1 CL2014000818A CL2014000818A CL2014000818A1 CL 2014000818 A1 CL2014000818 A1 CL 2014000818A1 CL 2014000818 A CL2014000818 A CL 2014000818A CL 2014000818 A CL2014000818 A CL 2014000818A CL 2014000818 A1 CL2014000818 A1 CL 2014000818A1
- Authority
- CL
- Chile
- Prior art keywords
- autism
- pyridazine
- schizophrenia
- pyrimidin
- ethynyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/22—Nitrogen and oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Liquid Crystal (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11184257 | 2011-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014000818A1 true CL2014000818A1 (es) | 2014-09-05 |
Family
ID=47016705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014000818A CL2014000818A1 (es) | 2011-10-07 | 2014-04-03 | Compuestos derivados de (fenil/heteroaril)-etinil-(piridin/pirimidin/piridazin)-acetamida, moduladores del receptor metabotropico de glutamato; procedimiento de preparacion; composicion farmaceutica; y su uso en esquizofrenia, enfermedades cognitivas, sindrome x-fragil o autismo |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8530472B2 (enExample) |
| EP (1) | EP2763969B1 (enExample) |
| JP (1) | JP5840794B2 (enExample) |
| KR (1) | KR101656966B1 (enExample) |
| CN (1) | CN103857658B (enExample) |
| AR (1) | AR088765A1 (enExample) |
| BR (1) | BR112014008078A2 (enExample) |
| CA (1) | CA2847096A1 (enExample) |
| CL (1) | CL2014000818A1 (enExample) |
| CO (1) | CO6900142A2 (enExample) |
| CR (1) | CR20140093A (enExample) |
| CY (1) | CY1117212T1 (enExample) |
| DK (1) | DK2763969T3 (enExample) |
| EA (1) | EA024993B1 (enExample) |
| ES (1) | ES2556796T3 (enExample) |
| HR (1) | HRP20160144T1 (enExample) |
| HU (1) | HUE026626T2 (enExample) |
| IL (1) | IL231439A (enExample) |
| IN (1) | IN2014CN02477A (enExample) |
| MX (1) | MX354414B (enExample) |
| PE (1) | PE20141555A1 (enExample) |
| PH (1) | PH12014500497A1 (enExample) |
| PL (1) | PL2763969T3 (enExample) |
| PT (1) | PT2763969E (enExample) |
| RS (1) | RS54511B1 (enExample) |
| SG (1) | SG11201401307WA (enExample) |
| SI (1) | SI2763969T1 (enExample) |
| TW (1) | TWI458710B (enExample) |
| UA (1) | UA110995C2 (enExample) |
| WO (1) | WO2013050460A1 (enExample) |
| ZA (1) | ZA201402068B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA113223C2 (xx) * | 2012-08-13 | 2016-12-26 | Арилетинілпіримідини | |
| EP2909178B1 (en) * | 2012-10-18 | 2016-10-05 | F. Hoffmann-La Roche AG | Ethynyl derivatives as modulators of mglur5 receptor activity |
| CR20170536A (es) | 2015-06-03 | 2018-02-01 | Hoffmann La Roche | Derivados de etinilo |
| DK3322701T3 (da) | 2015-07-15 | 2019-07-08 | H Hoffmann La Roche Ag | Ethynylderivater som metabotropiske glutamatreceptormodulatorer |
| CA3030788A1 (en) | 2016-07-18 | 2018-01-25 | F. Hoffmann-La Roche Ag | Ethynyl derivatives |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1303495T3 (da) * | 2000-07-24 | 2010-09-20 | Krenitsky Pharmaceuticals Inc | Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitet |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| US7776869B2 (en) | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
| WO2006048771A1 (en) | 2004-11-04 | 2006-05-11 | Addex Pharmaceuticals Sa | Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
| EP1863818B1 (en) * | 2005-03-23 | 2010-03-10 | F.Hoffmann-La Roche Ag | Acetylenyl-pyrazolo-pvrimidine derivatives as mglur2 antagonists |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| EP2162136A4 (en) | 2007-06-03 | 2012-02-15 | Univ Vanderbilt | GLUTAMATE METABOTROPIC POSITIVE RECEPTOR-BASED ALLOSTERIC-MODULATOR BENZAMIDE DERIVATIVES (MGLUR5) AND METHODS OF MAKING AND USING THEM |
| US8853392B2 (en) | 2007-06-03 | 2014-10-07 | Vanderbilt University | Benzamide mGluR5 positive allosteric modulators and methods of making and using same |
| MX2011000729A (es) | 2008-07-29 | 2011-03-15 | Boehringer Ingelheim Int | 5-alquinil-pirimidinas. |
| US8389536B2 (en) * | 2009-10-27 | 2013-03-05 | Hoffmann-La Roche Inc. | Positive allosteric modulators (PAM) |
-
2012
- 2012-04-10 UA UAA201404417A patent/UA110995C2/uk unknown
- 2012-09-27 US US13/628,128 patent/US8530472B2/en not_active Expired - Fee Related
- 2012-10-04 HR HRP20160144TT patent/HRP20160144T1/hr unknown
- 2012-10-04 BR BR112014008078A patent/BR112014008078A2/pt not_active Application Discontinuation
- 2012-10-04 SG SG11201401307WA patent/SG11201401307WA/en unknown
- 2012-10-04 TW TW101136751A patent/TWI458710B/zh not_active IP Right Cessation
- 2012-10-04 CA CA2847096A patent/CA2847096A1/en not_active Abandoned
- 2012-10-04 HU HUE12772100A patent/HUE026626T2/en unknown
- 2012-10-04 PH PH1/2014/500497A patent/PH12014500497A1/en unknown
- 2012-10-04 PT PT127721009T patent/PT2763969E/pt unknown
- 2012-10-04 WO PCT/EP2012/069605 patent/WO2013050460A1/en not_active Ceased
- 2012-10-04 KR KR1020147011407A patent/KR101656966B1/ko not_active Expired - Fee Related
- 2012-10-04 EA EA201490720A patent/EA024993B1/ru not_active IP Right Cessation
- 2012-10-04 DK DK12772100.9T patent/DK2763969T3/en active
- 2012-10-04 MX MX2014003636A patent/MX354414B/es active IP Right Grant
- 2012-10-04 CN CN201280049441.XA patent/CN103857658B/zh not_active Expired - Fee Related
- 2012-10-04 PE PE2014000497A patent/PE20141555A1/es active IP Right Grant
- 2012-10-04 PL PL12772100T patent/PL2763969T3/pl unknown
- 2012-10-04 EP EP12772100.9A patent/EP2763969B1/en active Active
- 2012-10-04 JP JP2014533888A patent/JP5840794B2/ja not_active Expired - Fee Related
- 2012-10-04 ES ES12772100.9T patent/ES2556796T3/es active Active
- 2012-10-04 SI SI201230401T patent/SI2763969T1/sl unknown
- 2012-10-04 IN IN2477CHN2014 patent/IN2014CN02477A/en unknown
- 2012-10-04 RS RS20160021A patent/RS54511B1/sr unknown
- 2012-10-05 AR ARP120103715A patent/AR088765A1/es unknown
-
2014
- 2014-02-26 CR CR20140093A patent/CR20140093A/es unknown
- 2014-02-28 CO CO14043441A patent/CO6900142A2/es unknown
- 2014-03-10 IL IL231439A patent/IL231439A/en active IP Right Grant
- 2014-03-20 ZA ZA2014/02068A patent/ZA201402068B/en unknown
- 2014-04-03 CL CL2014000818A patent/CL2014000818A1/es unknown
-
2016
- 2016-02-18 CY CY20161100141T patent/CY1117212T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3418281T3 (da) | Pyrazolo[1,5-a]pyrimidiner, der er anvendelige som inhibitorer af atr-kinase til behandling af cancersygdomme | |
| CR20140259A (es) | Compuestos novedosos de benzopirano, composiciones y usos de los mismos | |
| DK3238709T3 (da) | Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme | |
| IL239022B (en) | Tetracycline topical formulations, preparation and uses thereof | |
| DK3590928T3 (da) | Pyrimidinderivater til behandling af virusinfektioner | |
| DK3632919T3 (da) | Farmaceutiske sammensætninger omfattende imidazothiadiazol- og imidazopyrazinderivater som proteaseaktiverede receptor 4-(par4)- hæmmere til behandling af blodpladeaggregering | |
| CO7131375A2 (es) | Uracilos sustituidos bicíclicamente y uso de los mismos | |
| CL2014001280A1 (es) | Compuestos derivados de 4-fenil -piridinas sustituidas, moduladores del receptor de nk1; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento de la emesis, disfuncion vesical, depresion o ansiedad | |
| DK2718270T3 (da) | Sammensætninger og fremgangsmåder til fremstillingen af pyrimidin- og pyridinforbindelser med btk-hæmmende aktivitet | |
| BR112013011448A2 (pt) | composto, composição farnmacêutica, e, uso do composto | |
| CL2013001891A1 (es) | Compuestos heterociclicos fusionados; composicion farmaceutica y uso en el tratamiento de la degeneracion macular asociada con la edad. | |
| PT2709989T (pt) | Derivados de quinazolina para o tratamento de infeções virais e outras doenças | |
| BR112015000420A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| DK2462116T3 (da) | Fremgangsmåde til fremstillingen af farmaceutisk aktive forbindelser | |
| CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
| CL2015003444A1 (es) | Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo | |
| BR112014005669A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BR112014003567A2 (pt) | composto, uso de um composto, e, composição farmacêutica | |
| DK3040336T3 (da) | Forbindelser til brug i behandling af TYK2 Kinase-medierede tilstande | |
| DK2773648T3 (da) | Farmaceutiske forbindelser til anvendelse i behandlingen af clostridium difficile-infektion | |
| CO6970609A2 (es) | Composición farmacéutica y métodos de uso de derivados de 4-pregenen-11ß-17-21-triol-3,20-diona | |
| CL2014000819A1 (es) | Compuestos heterociclicos derivados de etinilo, moduladores alostericos mglur5; proceso de preparacion; composicion farmaceutica; uso en la prevencion o el tratamiento de esquizofrenia, enfermedades cognitivas, sindrome de la x fragil o autismo. | |
| CL2014000849A1 (es) | Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas. | |
| PL2919801T3 (pl) | Stabilna kompozycja farmaceutyczna białka fuzyjnego TNFR:FC etanerceptu | |
| CL2013003056A1 (es) | Compuestos derivados de (fenil o piridin)-etinil-(piridin o pirimidin) sustituido; composición farmacéutica que los comprende; proceso de preparación de esto; y su uso en el tratamiento de la esquizofrenia o enfermedades cognitivas. |